INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Inhibrx Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$89.79−0.04 (-0.04%)
Close on Oct 19, 2026
- Market cap
- $1.41B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
97.4%
14M of 15M shares
Institutional holders
163
52 new, 21 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
14 buys · 5 sales
Net bought $5.22M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Mark Lappe | 925,413 | 6.40% | 13D (active) amendment | Sep 12, 2024 |
| Bank Of America Corp /De/ | 857,318 | 5.90% | 13G (passive) | Jun 30, 2026 |
| Schonfeld Strategic Advisors LLC | 781,678 | 5.33% | 13G (passive) | Jun 30, 2026 |
| BlackRock, Inc. | 768,130 | 5.30% | 13G (passive) | Dec 31, 2025 |
| Joseph Edelman | 1,489,443 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| Ott David C. | 1,454,608 | 9.99% | 13G (passive) amendment | Dec 31, 2025 |
| Halvorsen Ole Andreas | 1,383,621 | 9.30% | 13G (passive) amendment | Jun 30, 2026 |
| Sanofi | 1,157,926 | 8.00% | 13G (passive) | May 30, 2024 |
| Morgan Stanley | 1,155,416 | 7.90% | 13G (passive) | Dec 31, 2025 |
| Jon Faiz Kayyem | 1,149,046 | 7.90% | 13D (active) amendment | Jun 3, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of INBX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Morgan Stanley | 1,308,051 | 8.89% | $123.94M | +44,973 | 0.01% |
| Perceptive Advisors LLC | 1,297,763 | 8.82% | $122.96M | −144,944 | 1.85% |
| Sanofi | 1,157,926 | 7.87% | $109.71M | – | 20.54% |
| Viking Global Investors LP | 1,123,929 | 7.64% | $106.49M | −313,776 | 0.30% |
| HighTower Advisors, LLC | 870,551 | 5.92% | $82.48M | +351 | 0.08% |
| Bank Of America Corp /De/ | 841,141 | 5.72% | $79.70M | +808,458 | 0.01% |
| BlackRock, Inc. | 825,972 | 5.61% | $78.26M | +27,074 | 0.00% |
| Schonfeld Strategic Advisors LLC | 697,586 | 4.74% | $66.10M | +442,759 | 0.24% |
| State Street Corp | 640,458 | 4.35% | $60.68M | +89,613 | 0.00% |
| Vanguard Capital Management LLC | 492,477 | 3.35% | $46.66M | +6,055 | 0.00% |
| Woodline Partners LP | 400,892 | 2.72% | $37.98M | +16,459 | 0.12% |
| Capital Research Global Investors | 363,050 | 2.47% | $34.40M | −29,797 | 0.00% |
| Goldman Sachs Group Inc | 338,176 | 2.30% | $32.04M | +243,102 | 0.00% |
| PFM Health Sciences, LP | 308,385 | 2.10% | $29.22M | +2,954 | 2.51% |
| Sofinnova Investments, Inc. | 303,103 | 2.06% | $28.72M | −102,926 | 1.48% |
| Healthcare Of Ontario Pension Plan Trust Fund | 271,700 | 1.85% | $25.74M | +101,000 | 0.04% |
| Parkman Healthcare Partners LLC | 256,950 | 1.75% | $24.35M | New | 2.49% |
| Geode Capital Management, LLC | 256,175 | 1.74% | $24.28M | +24,666 | 0.00% |
| First Turn Management, LLC | 164,783 | 1.12% | $15.61M | New | 1.67% |
| Millennium Management LLC | 147,200 | 1.00% | $13.95M | −180,660 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 163 | 14M | 97.4% | 52 / 56 | 39 / 21 | 3M | 2M |
| Q1 2026 | 135 | 13M | 86.4% | 25 / 53 | 36 / 27 | 2M | 1M |
| Q4 2025 | 138 | 13M | 87.0% | 45 / 38 | 38 / 8 | 3M | 1M |
| Q3 2025 | 102 | 11M | 71.4% | 25 / 23 | 34 / 11 | 2M | 2M |
| Q2 2025 | 88 | 10M | 70.9% | 10 / 22 | 34 / 14 | 1M | 1M |
| Q1 2025 | 92 | 11M | 73.3% | 9 / 18 | 37 / 16 | 1M | 1M |
| Q4 2024 | 102 | 11M | 76.1% | 17 / 31 | 30 / 10 | 3M | 1M |
| Q3 2024 | 96 | 9M | 60.7% | 22 / 35 | 18 / 11 | 2M | 2M |
| Q2 2024 | 87 | 10M | 66.0% | 87 / 0 | 0 / 0 | 10M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of INBX | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,645,973 | 11.18% | $1.07M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 794,436 | 5.40% | $1.33M | 0.00% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 401,027 | 2.72% | $38.00M | 0.35% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 369,641 | 2.51% | $35.02M | 0.00% | Jun 30, 2026 |
| SMALLCAP World Fund Inc | 353,292 | 2.40% | $33.47M | 0.04% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 244,118 | 1.66% | $23.13M | 0.03% | Jun 30, 2026 |
| The Merger Fund | 198,509 | 1.35% | $223.32K | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 193,298 | 1.31% | $322.81K | 0.00% | Jun 30, 2026 |
| Direxion Daily S&P Biotech Bull 3X Shares | 164,173 | 1.12% | $0 | 0.00% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 109,883 | 0.75% | $10.41M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 106,185 | 0.72% | $177.33K | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 103,938 | 0.71% | $8.53M | 0.03% | Jul 31, 2026 |
| Meridian Small Cap Growth Fund | 96,915 | 0.66% | $69.78K | 0.03% | Jun 30, 2026 |
| Tax-Managed U.S. Mid & Small Cap Fund | 95,150 | 0.65% | $61.61K | 0.00% | Jul 31, 2026 |
| iShares Biotechnology ETF | 76,625 | 0.52% | $7.26M | 0.08% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Mark Lappe | Chief Executive Officer, Director | 960,413 | 6.53% | Sep 28, 2026 |
| David Matly | President | – | – | Apr 27, 2026 |
| Kelly Deck | Chief Financial Officer | – | – | Apr 2, 2025 |
| Jon Faiz Kayyem | Director | 1,074,046 | 7.30% | Sep 23, 2026 |
| Douglas Forsyth | Director | 227,064 | 1.54% | Sep 18, 2026 |
| Kristiina Vuori MD | Director | 20,443 | 0.14% | Sep 18, 2026 |
| Kimberly Manhard | Director | 7,500 | 0.05% | Sep 18, 2026 |
| David C. Ott | 10% owner | – | – | Oct 9, 2025 |
| Global Opportunities GP LLC Viking | 10% owner | – | – | Oct 9, 2025 |
| Global Opportunities Illiquid Investments Sub-Master LP Viking | 10% owner | – | – | Oct 9, 2025 |
| Global Opportunities Portfolio GP LLC Viking | 10% owner | – | – | Oct 9, 2025 |
| Rose Sharon Shabet | 10% owner | – | – | Oct 9, 2025 |
| Global Opportunities Parent GP LLC Viking | 10% owner | 102,864 | 0.70% | Oct 9, 2025 |
| Ole Andreas Halvorsen | 10% owner | 83,333 | 0.57% | Oct 9, 2025 |
| Global Investors Lp Viking | 10% owner | – | – | Oct 9, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Mark Lappe Chief Executive Officer, Director | Sep 28, 2026 | Buy | +3,000 | $101.70 | $305.10K | 740,548 |
| Mark Lappe Chief Executive Officer, Director | Sep 28, 2026 | Buy | +1,500 | $98.88 | $148.32K | 737,548 |
| Mark Lappe Chief Executive Officer, Director | Sep 25, 2026 | Buy | +2,176 | $99.60 | $216.73K | 736,048 |
| Mark Lappe Chief Executive Officer, Director | Sep 25, 2026 | Buy | +3,324 | $98.87 | $328.64K | 733,872 |
| Jon Faiz Kayyem Director | Sep 23, 2026 | Buy | +5,000 | $100.00 | $500.00K | 434,360 |
| Jon Faiz Kayyem Director | Sep 16, 2026 | Buy | +5,000 | $100.00 | $500.00K | 429,360 |
| Kimberly Manhard Director | Sep 15, 2026 | Sale | −500 | $105.05 | $52.53K | 7,500 |
| Kimberly Manhard Director | Sep 14, 2026 | Sale | −500 | $110.26 | $55.13K | 8,000 |
| Kimberly Manhard Director | Sep 11, 2026 | Sale | −500 | $111.78 | $55.89K | 8,500 |
| Kimberly Manhard Director | Sep 9, 2026 | Sale | −500 | $115.80 | $57.90K | 9,000 |
| Kimberly Manhard Director | Sep 8, 2026 | Sale | −500 | $115.14 | $57.57K | 9,500 |
| Douglas Forsyth Director | Sep 8, 2026 | Buy | +2,500 | $114.65 | $286.63K | 227,064 |
| Mark Lappe Chief Executive Officer, Director | Sep 8, 2026 | Buy | +1,100 | $107.12 | $117.83K | 719,148 |
| Mark Lappe Chief Executive Officer, Director | Sep 8, 2026 | Buy | +6,605 | $100.64 | $664.73K | 718,048 |
| Mark Lappe Chief Executive Officer, Director | Sep 8, 2026 | Buy | +5,895 | $99.29 | $585.31K | 711,443 |
| Mark Lappe Chief Executive Officer, Director | Sep 8, 2026 | Buy | +1,219 | $111.88 | $136.38K | 720,867 |
| Mark Lappe Chief Executive Officer, Director | Sep 8, 2026 | Buy | +9,681 | $112.28 | $1.09M | 730,548 |
| Mark Lappe Chief Executive Officer, Director | Sep 8, 2026 | Buy | +500 | $108.24 | $54.12K | 719,648 |
| Jon Faiz Kayyem Director | Sep 8, 2026 | Buy | +5,000 | $113.52 | $567.60K | 424,360 |
| Global Opportunities Parent GP LLC Viking 10% owner | Oct 7, 2025 | Sale | −25,042 | $32.25 | $807.60K | 102,864 |
| Global Opportunities Parent GP LLC Viking 10% owner | Oct 7, 2025 | Sale | −308,643 | $32.25 | $9.95M | 1,267,823 |
| Global Opportunities Parent GP LLC Viking 10% owner | Oct 7, 2025 | Sale | −16,315 | $32.25 | $526.16K | 67,018 |
| Jon Faiz Kayyem Director | Mar 27, 2025 | Gift | −90,000 | – | – | 419,360 |
| Jon Faiz Kayyem Director | Dec 16, 2024 | Gift | +250,000 | – | – | 250,000 |
| Jon Faiz Kayyem Director | Dec 16, 2024 | Gift | −500,000 | – | – | 509,360 |
| Jon Faiz Kayyem Director | Dec 16, 2024 | Gift | +250,000 | – | – | 250,000 |
| Jon Faiz Kayyem Director | Dec 6, 2024 | Gift | −52,000 | – | – | 1,009,360 |
| Jon Faiz Kayyem Director | Nov 20, 2024 | Buy | +18,750 | $14.19 | $266.06K | 69,843 |
| Jon Faiz Kayyem Director | Nov 20, 2024 | Buy | +18,750 | $14.19 | $266.06K | 69,843 |
| Jon Faiz Kayyem Director | Nov 19, 2024 | Buy | +34,843 | $14.23 | $495.82K | 51,093 |
| Jon Faiz Kayyem Director | Nov 19, 2024 | Buy | +34,843 | $14.23 | $495.82K | 51,093 |
| Kristiina Vuori MD Director | Oct 3, 2024 | Buy | +6,667 | $15.00 | $100.01K | 20,443 |
| Mark Lappe Chief Executive Officer, Director | Sep 16, 2024 | Buy | +13,037 | $17.13 | $223.32K | 705,548 |
| Mark Lappe Chief Executive Officer, Director | Sep 12, 2024 | Buy | +26,963 | $15.05 | $405.79K | 692,511 |
| Kristiina Vuori MD Director | Sep 11, 2024 | Buy | +6,457 | $15.07 | $97.31K | 13,776 |
| Kristiina Vuori MD Director | Sep 10, 2024 | Buy | +179 | $15.00 | $2.69K | 7,319 |
| Mark Lappe Chief Executive Officer, Director | Sep 10, 2024 | Buy | +8,500 | $15.19 | $129.12K | 665,548 |
| Mark Lappe Chief Executive Officer, Director | Sep 9, 2024 | Buy | +9,500 | $15.21 | $144.50K | 657,048 |
| Mark Lappe Chief Executive Officer, Director | Sep 6, 2024 | Buy | +26,000 | $15.29 | $397.54K | 647,548 |
| Mark Lappe Chief Executive Officer, Director | Sep 3, 2024 | Buy | +15,288 | $15.66 | $239.41K | 160,288 |
| Mark Lappe Chief Executive Officer, Director | Sep 3, 2024 | Buy | +4,712 | $16.31 | $76.85K | 165,000 |
| Mark Lappe Chief Executive Officer, Director | Aug 30, 2024 | Buy | +10,000 | $14.02 | $140.20K | 145,000 |
| Kristiina Vuori MD Director | Aug 29, 2024 | Buy | +7,140 | $14.00 | $99.96K | 7,140 |
| Mark Lappe Chief Executive Officer, Director | Aug 29, 2024 | Buy | +10,000 | $14.03 | $140.30K | 135,000 |
| Kimberly Manhard Director | Aug 28, 2024 | Buy | +10,000 | $13.98 | $139.80K | 10,000 |
| Douglas Forsyth Director | Aug 23, 2024 | Buy | +59,812 | $14.07 | $841.55K | 224,564 |
| Douglas Forsyth Director | Aug 22, 2024 | Buy | +15,188 | $12.89 | $195.77K | 164,752 |
| Mark Lappe Chief Executive Officer, Director | Aug 21, 2024 | Buy | +12,945 | $12.93 | $167.38K | 54,865 |
| Mark Lappe Chief Executive Officer, Director | Aug 20, 2024 | Buy | +27,055 | $12.97 | $350.90K | 41,920 |
| Jon Faiz Kayyem Director | Jun 24, 2024 | Gift | +10,000 | – | – | 16,250 |
| Jon Faiz Kayyem Director | Jun 24, 2024 | Gift | −89,050 | – | – | 1,061,360 |
| Jon Faiz Kayyem Director | Jun 24, 2024 | Gift | +10,000 | – | – | 16,250 |
| Jon Faiz Kayyem Director | Jun 5, 2024 | Buy | +49,284 | $17.23 | $849.16K | 1,142,145 |
| Jon Faiz Kayyem Director | Jun 5, 2024 | Buy | +8,265 | $17.89 | $147.86K | 1,150,410 |
| Jon Faiz Kayyem Director | Jun 4, 2024 | Buy | +23,726 | $18.24 | $432.76K | 1,092,861 |
| Jon Faiz Kayyem Director | Jun 4, 2024 | Buy | +65,337 | $17.44 | $1.14M | 1,069,135 |
| Jon Faiz Kayyem Director | Jun 3, 2024 | Buy | +46,792 | $16.61 | $777.22K | 923,060 |
| Jon Faiz Kayyem Director | Jun 3, 2024 | Buy | +80,738 | $17.90 | $1.45M | 1,003,798 |
| Jon Faiz Kayyem Director | May 31, 2024 | Buy | +70,193 | $16.14 | $1.13M | 876,268 |
| Inhibrx, Inc. 10% owner | May 29, 2024 | Other | −13,316,140 | – | – | 1,157,926 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Kimberly Manhard Director | Sep 15, 2026 | 500 | $52.53K | Sep 15, 2026 | Open Market Purchase |
| Kimberly Manhard Director | Sep 14, 2026 | 500 | $55.13K | Sep 14, 2026 | Open Market Purchase |
| Kimberly Manhard Director | Sep 11, 2026 | 500 | $55.89K | Sep 11, 2026 | Open Market Purchase |
| Kimberly Manhard Director | Sep 9, 2026 | 500 | $57.90K | Sep 9, 2026 | Open Market Purchase |
| Kimberly Manhard Director | Sep 8, 2026 | 500 | $57.57K | Sep 8, 2026 | Open Market Purchase |